ABSTRACT
Molecular neuroimaging techniques such as positron emission tomography (PET) have been used for the in vivo assessment of molecular processes at their sites of action, permitting detection of subtle pathophysiological changes in the brain at asymptomatic stages, when there is no evidence of anatomic changes on computed tomography (CT) or magnetic resonance imaging (MRI). e development of molecular imaging methods for non-invasively assessing disease-specic traits such as beta-amyloid (Aβ) or tau in Alzheimer’s disease (AD) is allowing early diagnosis at presymptomatic stages, more accurate dierential diagnosis as well as, when available, the evaluation and monitoring of disease-modifying therapy (Table 12.1) (Villemagne and Okamura, 2014; Rowe and Villemagne, 2011).
